EGFR and non-small cell lung carcinoma: And for NSCLC patients with leptomeningeal metastasis, it has been confirmed that erlotinib may improve their clinical outcome after initial failure of gefitinib and apatinib.[47] We summarized the treatment process after gefitinib resistance and the characteristics of patients suitable for continuing EGFR-TKI treatment (Figure 2).